Celgene Gains Buyout Option with VentiRx Cancer Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 27 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1825 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Celgene has formed a global collaboration with the virtual company VentiRx Pharmaceuticals to fund Phase II trials of VentiRx’s TLR8 (Toll-like receptor 8) agonist VTX-2337 in ovarian and head-and-neck cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS